Serial No.:

10/079,452 20832Y

Case No.: Page No.:


3

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1(currently amended): A compound having the formula (I):



or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 5-7 membered ring containing 1 or 2 nitrogen ring atoms or an aza bicyclo octane ring;

HetAr is a 5 or 6 membered heteroaromatic ring containing 1-3 nitrogen ring atoms, or isoxazolyl, thiazolyl, thiadiazolyl, quinolinyl, quinazolinyl, purinyl, pteridinyl, benzimidazolyl, pyrrolopyrimidinyl, or imidazopyridinyl;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—, $-N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH₂—, (C_{1-2} alkyl)HNCH₂—, Si(CH₃)3—C—, or NH₂C(O)—;

A is -C1-4alkyl-;

B is $aryl(CH_2)_{0.3}$ –O-C(O)–, heteroaryl(CH₂)₁₋₃–O-C(O)–, indanyl(CH₂)_{0.3}–O-C(O)–, aryl(CH₂)₁₋₃–C(O)–, aryl-cyclopropyl–C(O)–, heteroaryl-cyclopropyl–C(O)–, heteroaryl(CH₂)₁₋₃–C(O)–, [[aryl(CH₂)₁₋₃–,]] [[heteroaryl(CH₂)₁₋₃–,]] aryl(CH₂)₁₋₃–NH–C(O)–, aryl(CH₂)₁₋₃–SO₂–, heteroaryl(CH₂)₁₋₃–SO₂–, wherein any of the

Serial No.: 10/079,452 Case No.: 20832Y

Page No.: 4

aryl or heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{1-4} alkoxy, trifluoromethyl, bromo, fluoro, or chloro; and

X is H, OH, F, C₁₋₄alkyl, C₁₋₄alkoxy, NH₂, or X taken with an adjacent bond is =0.

Claim 2(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₀₋₃-O-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 3(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom;

HetAr is optionally substituted with 1 or 2 substituents, each substituent
independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_
4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-,
heteroarylethynyl-,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2-, (C1_2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-

Claim 4(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is an isoxazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,—N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2—, (C1_2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 5(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

10/079,452 20832Y

Page No.:

5

HetAr is a thiadiazolyl optionally substituted with I or 2 substituents, each substituent independently is C1-4alkyl, C1-4alkoxy, C2-4alkynyl, trifluoromethyl, hydroxy, hydroxyC1-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0-4alkyl)(C0-4alkyl), nitro, (C1-2alkyl)(C1-2alkyl)NCH2-, (C1-2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

Claim 6(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 5 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2—, (C1_2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 7(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2-, (C1_2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

Claim 8(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,—N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2—, (C1_2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

10/079,452 20832Y

Page No.:

6

Claim 9(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 10(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is thiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁_4alkyl, C₁_4alkoxy, C₂_4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N(C₀_4alkyl)(C₀_4alkyl), nitro, (C₁_2alkyl)(C₁_2alkyl)NCH₂—, (C₁_2alkyl)HNCH₂—, Si(CH₃)3—C—, or NH₂C(O)—.

Claim 11(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,—N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2—, (C1_2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 12(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrrolopyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

10/079,452 20832Y

Page No.:

7

Claim 13(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂₋, (C₁₋₂alkyl)HNCH₂₋, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 14(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C1-4alkyl, C1-4alkoxy, C2-4alkynyl, trifluoromethyl, hydroxy, hydroxyC1-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0-4alkyl)(C0-4alkyl), nitro, (C1-2alkyl)(C1-2alkyl)NCH2-, (C1-2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

Claim 15(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₁₋₃-SO₂-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 16(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,—N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2—, (C1_2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

10/079,452 20832Y

Page No.:

200

Claim 17(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinazolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2-, (C1_2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

Claim 18(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁_4alkyl, C₁_4alkoxy, C₂_4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,—N(C₀_4alkyl)(C₀_4alkyl), nitro, (C₁_2alkyl)(C₁_2alkyl)NCH₂—, (C₁_2alkyl)HNCH₂—, Si(CH₃)3—C—, or NH₂C(O)—.

Claim 19(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C_0 -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH2-, (C_1 -2alkyl)HNCH2-, Si(C_1 -3alkyl)-C-, or NH2C(O_1 -2alkyl)-.

Claim 20(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-,

Serial No.: Case No.: Page No.: 10/079,452 20832Y

heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 21(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 5 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)_{0.3}-O-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 22(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C1_4alkyl, C1_4alkoxy, C2_4alkynyl, trifluoromethyl, hydroxy, hydroxyC1_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N(C0_4alkyl)(C0_4alkyl), nitro, (C1_2alkyl)(C1_2alkyl)NCH2—, (C1_2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 23(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁_4alkyl, C₁_4alkoxy, C₂_4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,—N(C₀_4alkyl)(C₀_4alkyl), nitro, (C₁_2alkyl)(C₁_2alkyl)NCH₂—, (C₁_2alkyl)HNCH₂—, Si(CH₃)3—C—, or NH₂C(O)—.

Claim 24(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁_4alkyl, C₁_4alkoxy, C₂_4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl, phenylethynyl,

10/079,452 20832Y

Pag No.:

10

heteroarylethynyl-,- $N(C_{0-4}alkyl)(C_{0-4}alkyl)$, nitro, $(C_{1-2}alkyl)(C_{1-2}alkyl)NCH_{2-}$, $(C_{1-2}alkyl)HNCH_{2-}$,

Claim 25(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁_4alkyl, C₁_4alkoxy, C₂_4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N(C₀_4alkyl)(C₀_4alkyl), nitro, (C₁_2alkyl)(C₁_2alkyl)NCH₂—, (C₁_2alkyl)HNCH₂—, Si(CH₃)3—C—, or NH₂C(O)—.

Claim 26(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is aryl(CH₂)_{0.3}-O-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 27(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom, and HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁_4alkyl, C₁_4alkoxy, C₂_4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁_4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N(C₀_4alkyl)(C₀_4alkyl), nitro, (C₁_2alkyl)(C₁_2alkyl)NCH₂—, (C₁_2alkyl)HNCH₂—, Si(CH₃)3—C—, or NH₂C(O)—.

Claim 28(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁_4alkyl, C₁_4alkoxy, C₂_4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁, 4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—,

Serial No.: Case No.: Page No.:

20832Y 11

10/079,452

heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 29(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atom; and HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 30(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is $aryl(CH_2)_{1-3}$ –SO₂–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 31(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom, and B is heteroaryl(CH₂)₁₋₃-C(O)-, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 32(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)_{1.3}-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Serial No.: 10/079,452 Case No.: 20832Y Page No.: 12

Claim 33(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl-cyclopropyl-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 34(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyridyl optionally substituted with 1 or 2 substituents, each substituent independently is C1-4alkyl, C1-4alkoxy, C2-4alkynyl, trifluoromethyl, hydroxy, hydroxyC1-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0-4alkyl)(C0-4alkyl), nitro, (C1-2alkyl)(C1-2alkyl)NCH2-, (C1-2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-

Claim 35(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 36(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyridazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

10/079,452 20832Y

Page No.:

13

Claim 37(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 38(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is heteroaryl(CH₂)_{1.3}-O-C(O)-, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro;

Claim 39(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₁₋₃-NH-C(NCN)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 40(original): The compound according to Claim 1, wherein said compound is

Serial No.:

10/079,452 20832Y

Case No.: Page No.:

| N NH NH | |
|---------|--|
| | |
| | |

Serial No.: Case No.: Page No.:

10/079,452 20832Y 15

10/079,452 20832.Y

Page No.:

| - N HN-CN | | |
|------------|-----------------|--|
| | | N OH OH |
| | CH ₃ | O D D D D D D D D D D D D D D D D D D D |
| HN N NC | HN | O N HN N N N N N N N N N N N N N N N N N |
| | N H OH | |

10/079,452 20832Y

Page No.:

| HO NH O | N- NH C N- S | |
|---|---|-----------------|
| | O N N N N N N N N N N N N N N N N N N N | Br NH |
| N NH NH | | |
| CI NH NH | | |
| CI NO IN NO | | NH ₂ |

Serial No.: Case No.: Page No.:


10/079,452 20832Y

| | | F N H N N N N N N N N N N N N N N N N N |
|---|--------|---|
| | | CI NH NH NH NH |
| | | N N N N N N N N N N N N N N N N N N N |
| FL'N No Co | | |
| | NH C | N HN N |
| HN NO | HN_N C | HN N N SO |

10/079,452 20832Y

Page No.:

19



or a pharmaceutically acceptable salt thereof.

Claim 41(original): The compound according to Claim 1, wherein said compound is

| N HN O | LN HN ON OFF | HAN NO |
|---------------------------------------|---------------------------------------|--|
| N N N N N N N N N N N N N N N N N N N | | 0=9=0 2 2 2 2 3 = 0 |
| N N N N N N N N N N N N N N N N N N N | N N N N N N N N N N N N N N N N N N N | 0= s=0 |
| | N NH NH | N N N N N N N N N N N N N N N N N N N |
| NH NH SHOW | F-N-NH OF S | \$ 2 |

10/079,452 20832Y

Page No.:

2003

or a pharmaceutically acceptable salt thereof.

Claim 42(withdrawn):

The compound according to Claim 1, wherein said compound is

or a pharmaceutically acceptable salt thereof.

Claim 43(original): The compound according to Claim 1, wherein said compound is

10/079,452 20832Y

Page No.:

21

or a pharmaceutically acceptable salt thereof.

Claim 44(previously presented): The compound according to Claim 1, wherein said compound is

10/079,452 20832Y

Page No.:

| | HN N N |
|--------------------|--|
| HN NH ₂ | |
| | |
| | ON THE PROPERTY OF THE PROPERT |

10/079,452 20832Y

Page No.:

23

or a pharmaceutically acceptable salt thereof.

Claim 45(previously presented): The compound according to Claim 1, wherein said compound is

10/079,452 20832Y

| | HN N=F |
|---|--------|
| HN-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N- | |

Serial No.: Case No.: Page No.:

10/079,452 20832Y

| | F Z Z Z Z | HN—N—Br |
|---|-----------|---------|
| (N) N N N N N N N N N N N N N N N N N N | N-N-N- | |
| | | |
| | | |
| | | |
| | | |

10/079,452 20832Y

Page No.:

26

| | · · · · · · · · · · · · · · · · · · · |
|-------------|---------------------------------------|
| | |
| | |
| | |
| F C N F F F | |
| N H F | |

or a pharmaceutically acceptable salt thereof.

Claim 46(previously presented): The compound according to Claim 1, wherein said compound is

10/079,452 Serial No.: 20832Y Case No.: Page No.:

or a pharmaceutically acceptable salt thereof.

Claim 47(withdrawn): The compound according to Claim 1, wherein said compound is

or a pharmaceutically acceptable salt thereof.

Claim 48(original): A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to claim 1.

Claim 49(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat pain.

Claim 50(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke.

Claim 51(original): A method of treating pain comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.

10/079,452 20832Y

Page No.:

28

Claim 52(original): A method of treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.